A phase1b study of navicixizumab plus FOLFIRI in second-line treatment of patients with metastatic colorectal cancer.
- Resource Type
- Article
- Source
- Journal of Clinical Oncology; 2/1/2023 Supplement 1, Vol. 41, p111-111, 1p
- Subject
- Language
- ISSN
- 0732183X